Peroxisome proliferator-activated receptor α-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells

European Journal of Pharmacology

Volumn 556, Issue 1-3, 2007, Pages 172-180

  Yamashita, Masamichi ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Inflammation; Leukotriene; Mast cells; Peroxisome proliferator; Peroxisome proliferator activated receptor ; RBL 2H3

Indexed keywords

ACYL COENZYME A OXIDASE; ANTIGEN; ARACHIDONATE 5 LIPOXYGENASE; CALCIMYCIN; FENOFIBRATE; IMMUNOGLOBULIN E; MESSENGER RNA; PEPTIDOLEUKOTRIENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPASE A2; PIRINIXIC ACID; TROGLITAZONE;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; INCUBATION TIME; LIVER CELL; MAST CELL; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SENSITIZATION;

ACYL-COA OXIDASE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; CYSTEINE; FENOFIBRATE; HEXOSAMINIDASES; IMMUNOGLOBULIN E; LEUKOTRIENES; MACROPHAGES, PERITONEAL; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXISOME PROLIFERATORS; PHOSPHOLIPASES A; PPAR ALPHA; PYRIMIDINES; RATS;

EID: 33846034417     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.032     Document Type: Article

References (51)

1. Ashino S., Yamashita M., Okuyama K., Kitabatake Y., Oshima Y., Kawamura S., and Takayanagi M. Effects of the inhibition of prostaglandin production on leukotriene production in rat mast cell line RBL-2H3. J. Tohoku Pharmacol. Univ. 49 (2003) 131-136
2. Banfi C., Auwerx J., Poma F., Tremoli E., and Mussoni L. Induction of plasminogen activator inhibitor I by the PPARα ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thromb. Haemost. 90 (2003) 611-619
3. Barnes N.C., and Pujet J.C. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52 (1997) 523-527
4. Belvisi M.G., Hele D.J., and Birrell M.A. Peroxisome proliferator-activated receptor γ agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol. 533 (2006) 101-109
5. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., and Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 (2006) 789-799
6. Chakrabarti R., Misra P., Vikramadithyan R.K., Premkumar M., Hiriyan J., Datla S.R., Damarla R.K., Suresh J., and Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-α and PPAR-γ. Eur. J. Pharmacol. 491 (2004) 195-206
7. 4 synthase. J. Biol. Chem. 277 (2002) 28902-28908
8. Cornu-Chagnon M.C., Dupont H., and Edgar A. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 26 (1995) 63-74
9. Dahlen B., Nizankowska E., Szczeklik A., Zetterstrom O., Bochenek G., Kumlin M., Mastalerz L., Pinis G., Swanson L.J., Boodhoo T.I., Wright S., Dube L.M., and Dahlen S.-E. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am. J. Respir. Crit. Care Med. 157 (1998) 1187-1194
10. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., and Wrighton S.A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290 (1999) 854-862
11. Desager J.P., Horsmans Y., Vandenplas C., and Harvengt C. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 124 (1996) S65-S73
12. Fish J.E., Kemp J.P., Lockey R.F., Glass M., Hanby L.A., Bonuccelli C.M., and The Zafirlukast Trialists Group. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin. Ther. 19 (1997) 675-690
13. Gay C.A., and Gebicki J.M. Perchloric acid enhances sensitivity and reproducibility of the ferric-xylenol orange peroxide assay. Anal. Biochem. 304 (2002) 42-46
14. 4 and cystinyl-bis-glycine metabolism in membrane-bound dipeptidase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4859-4863
15. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., Stocco R., Bellefeuille J.N., Abramovitz M., Cheng R., Williams Jr. D.L., Zeng Z., Liu Q., Ma L., Clements M.K., Coulombe N., Liu Y., Austin C.P., George S.R., O'Neill G.P., Metters K.M., Lynch K.R., and Evans J.F. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275 (2000) 30531-30536
16. Hoekstra M., Kruijt J.K., Van Eck M., and Van Berkel T.J. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J. Biol. Chem. 278 (2003) 25448-25453
17. Irani A.M., and Schwartz L.B. Human mast cell heterogeneity. Allergy Proc. 15 (1994) 303-308
18. Irani A.A., Craig S.S., Nilsson G., Ishizaka T., and Schwartz L.B. Characterization of human mast cells developed in vitro from fetal liver cells cocultured with murine 3T3 fibroblasts. Immunology 77 (1992) 136-143
19. James G.W. The use of the in vivo trachea preparation of the guinea-pig to asses drug action on lung. J. Pharm. Pharmacol. 21 (1969) 379-386
20. Kitabatake Y., Kawamura S., Yamashita M., Okuyama K., Takayanagi M., and Ohno I. The expression of mRNA for calcitonin gene-related peptide receptors in a mucosal type mast cell line, RBL-2H3. Biol. Pharm. Bull. 27 (2004) 896-898
21. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
22. 1 receptor. Nature 399 (1999) 789-793
23. Meredith C., Scott M.P., Renwick A.B., Price R.J., and Lake B.G. Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. Xenobiotica 33 (2003) 511-527
24. Morita Y., and Siraganian R.P. Inhibition of IgE-mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation. J. Immunol. 127 (1981) 1339-1344
25. Nicol C.J., Yoon M., Ward J.M., Yamashita M., Fukamachi K., Peters J.M., and Gonzalez F.J. PPAR γ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 25 (2004) 1747-1755
26. Offermanns S., Jones S.V., Bombien E., and Schultz G. Stimulation of mitogen-activated protein kinase activity by different secretory stimuli in rat basophilic leukemia cells. J. Immunol. 152 (1994) 250-261
27. Okuyama K., Yamashita M., Kitabatake Y., Kawamura S., Takayanagi M., and Ohno I. Ciglitazone inhibits the antigen-induced leukotrienes production independently of PPAR γ in RBL-2H3 mast cells. Eur. J. Pharmacol. 521 (2005) 21-28
28. Pan J., Xiang Q., Renwick A.B., Price R.J., Ball S.E., Kao J., Scatina J.A., and Lake B.G. Use of a quantitative real-time reverse transcription-polymerase chain reaction method to study the induction of CYP1A, CYP2B and CYP4A forms in precision-cut rat liver slices. Xenobiotica 32 (2002) 739-747
29. Pauley C.J., Ledwith B.J., and Kaplanski C. Peroxisome proliferators activate growth regulatory pathways largely via peroxisome proliferator-activated receptor α-independent mechanisms. Cell. Signal. 14 (2002) 351-358
30. Peebles R.S., and Glauert H.P. Effect of phenobarbital on hepatic eicosanoid concentrations in rats. Arch. Toxicol. 71 (1997) 646-650
31. Pons F., Haag M., Corcos L., Bonnet P., Guillouzo A., Lugnier A., and Frossard N. Inhalation of toluene diisocyanate affects cytochrome P450 2B1 expression in rat lung. Arch. Toxicol. 74 (2000) 397-403
32. Radmark O., and Samuelsson B. Regulation of 5-lipoxygenase enzyme activity. Biochem. Biophys. Res. Commun. 338 (2005) 102-110
33. Raulf M., Stuning M., and Konig W. Metabolism of leukotrienes by L-γ-glutamyl-transpeptidase and dipeptidase from human polymorphonuclear granulocytes. Immunology 55 (1985) 135-147
34. Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.W., Kundu S., and Zhang J. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52 (1997) 45-48
35. Schrader J.W., Lewis S.J., Clark-Lewis I., and Culvenor J.G. The persisting (P) cell: histamine content, regulation by a T cell-derived factor, origin from a bone marrow precursor, and relationship to mast cells. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 323-327
36. 4 synthase gene in the monocyte-like cell line, THP-1. J. Immunol. 170 (2003) 2121-2128
37. 4 synthesis in vivo and attenuation of the acute inflammatory response. Mol. Cell. Biol. 21 (2001) 5389-5395
38. Shin M., Kim I., Inoue Y., Kimura S., and Gonzalez F.J. Regulation of mouse hepatic α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase, a key enzyme in the tryptophan-NAD pathway, by hepatocyte nuclear factor 4α and peroxisome-proliferator activated receptor α. Mol. Pharmacol. 70 (2006) 1281-1290
39. Sorensen H.N., Hvattum E., Paulssen E.J., Gautvik K.M., Bremer J., and Spydevold O. Induction of peroxisomal acyl-CoA oxidase by 3-thia fatty acid, in hepatoma cells and hepatocytes in culture is modified by dexamethasone and insulin. Biochim. Biophys. Acta 1171 (1993) 263-271
40. Sridhar C., Subbaraju G.V., Venkateswarlu Y., and Venugopal R.T. New acylated iridoid glucosides from Vitex altissima. J. Nat. Prod. 67 (2004) 2012-2016
41. Steinhilber D. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. 69 (1994) 3-14
42. Strobel S., Miller H.R., and Ferguson A. Human intestinal mucosal mast cells: evaluation of fixation and staining techniques. J. Clin. Pathol. 34 (1981) 851-858
43. Sugiyama H., Nonaka T., Kishimoto T., Komoriya K., Tsuji K., and Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur. J. Immunol. 30 (2000) 3363-3370
44. Sugiyama H., Nonaka T., Kishimoto T., Komoriya K., Tsuji K., and Nakahata T. Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. FEBS Lett. 467 (2000) 259-262
45. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992) 433-439
46. Wahli W., Braissant O., and Desvergne B. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem. Biol. 2 (1995) 261-266
47. Werz O., and Steinhilber D. Development of 5-lipoxygenase inhibitors-lessons from cellular enzyme regulation. Biochem. Pharmacol. 70 (2005) 327-333
48. Werz O., Klemm J., Samuelsson B., and Radmark O. 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5261-5266
49. Yamashita M., Kushihara M., Hirasawa N., Takasaki W., Takahagi H., Takayanagi M., and Ohuchi K. Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. Br. J. Pharmacol. 129 (2000) 367-373
50. 2 by the anti-rheumatic gold compounds. J. Pharm. Pharmacol. 55 (2003) 245-251
51. Zhang C., Baumgartner R.A., Yamada K., and Beaven M.A. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-α and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J. Biol. Chem. 272 (1997) 13397-13402